Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.47 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17145370 | 0.87 | ELANE (0.48) | LOXBCAT2GAACA1CA2 | |
| SCHEMBL6555605 | 0.87 | MYC (0.48) | LOXBCAT2DRD2HSD11B1SMN1; SMN2 | |
| SCHEMBL30690139 | 0.87 | ALDH1A1 (0.44) | LOXBCAT2GAACA1CA2 | |
| SCHEMBL391939 | 0.87 | CA2 (0.56) | LOXCA1CA2CA4CA6 | |
| SCHEMBL1925733 | 0.87 | LOX (0.41) | LOXBCAT2GAACA1CA2 | |
| SCHEMBL489571 | 0.87 | ALDH1A1 (0.44) | LOXBCAT2GAACA1CA2 | |
| Hydrochloric Acid SCHEMBL28234811 | 0.84 | MYC (0.47) | LOXBCAT2DRD2HSD11B1SMN1; SMN2 | |
| SCHEMBL13268425 | 0.84 | L3MBTL1 (0.43) | LOXBCAT2GAADRD2HSD11B1 | |
| Hydrochloric Acid SCHEMBL5740459 | 0.84 | CA2 (0.54) | LOXCA1CA2CA4CA6 | |
| Hydrochloric Acid SCHEMBL6754825 | 0.84 | CA2 (0.54) | LOXCA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2021-02-04 | — | — | US | disclosed |
| US-10703712-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10626081-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-8658650-B2 | Substituted 1,1,3,1-tetraoxidobenzo[D][1,3,2]dithiazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY | 2014-02-25 | — | — | US | disclosed |
| US-20110319429-A1 | SUBSTITUTED 1,1,3,1-TETRAOXIDOBENZO[D][1,3,2]DITHIAZOLES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2011-12-29 | — | — | US | disclosed |
| US-7754347-B2 | Organic electroluminescent device | FUJIFILM CORPORATION (JP) | 2010-07-13 | — | — | US | disclosed |
| US-7754347-B2 | Organic electroluminescent device | FUJIFILM CORPORATION (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20090221589-A1 | Use of aminoalcohol derivatives for the treatment of overactive bladder | TRIESELMANN THOMAS | 2009-09-03 | — | — | US | disclosed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-7214698-B2 | Beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-08 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070072003-A1 | Organic electroluminescent device | FUJI PHOTO FILM CO., LTD. | 2007-03-29 | — | — | US | disclosed |
| US-20070072003-A1 | Organic electroluminescent device | FUJI PHOTO FILM CO., LTD. | 2007-03-29 | — | — | US | disclosed |
| US-6054254-A | COATING WITH PHOTORESISTS, EXPOSURE TO LIGHT, DEVELOPMENT | KABUSHIKI KAISHA TOSHIBA (JP) | 2000-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319429-A1 | SUBSTITUTED 1,1,3,1-TETRAOXIDOBENZO[D][1,3,2]DITHIAZOLES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRM1, GRM4, GRIK4 | LOX 3420/4885BCAT2 1754/4885GAA 3984/4885 |
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | LOX 816/4885BCAT2 2653/4885GAA 782/4885 |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | LOX 816/4885BCAT2 2653/4885GAA 782/4885 |
| US-20090221589-A1 | Use of aminoalcohol derivatives for the treatment of overactive bladder | ADRB2, ADRB1, ADRB3 | LOX 1965/4885BCAT2 70/4885GAA 1985/4885 |
| US-10703712-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | LOX 816/4885BCAT2 2653/4885GAA 782/4885 |
| US-10626081-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | LOX 816/4885BCAT2 2653/4885GAA 782/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | LOX 2729/4885BCAT2 1202/4885GAA 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.